Intravitreal bevacizumab for treatment of myopic choroidal neovascularization: the second year of a prospective study.

Abstract

Eyes with myopic CNV treated with intravitreal bevacizumab over 2 years had significant anatomic and functional improvement. Further studies will be needed to confirm the long-term efficacy and safety of this treatment.